The Joint Commission, which currently has accredited about 22,000 organizations in the U.S. and abroad, recently stirred controversy when it suspended its Top Performer award program for 2016, citing a need to review its quality measures. CEO Dr. Mark Chassin discusses the move with Modern Healthcare reporter Sabriya Rice. Here is an edited transcript of their discussion.
Q&A: Joint Commission CEO Dr. Mark Chassin on suspending Top Performer program
Chassin
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Sponsored Content